# CoV_PLE_concept_sets
covid PLE concept sets for Exposures

Currents sets to be developed 

DMARDs

Ts:
•	Hydroxychloroquine (ingredient)
•	Tocilizumab (ingredient)
•	Baricitinib (ingredient)
Cs: 
•	Methotrexate (ingredient)
•	Sulfasalazine (ingredient)

Anti-HIV antiviral therapies

Ts:
•	Protease inhibitors [-navir] (class)
o	Umifenovir (ingredient)
o	Remdesivir (ingredient)
o	Lopinavir (ingredient) 
o	Ritonavir (ingredient)

Cs: 
•	Integrase inhibitors (class) (includes raltegravir, elvitegravir, dolutegravir, bictegravir)
•	Non-nucleoside reverse transcriptase inhibitors (class) (included efavirenz, nevirapine, delavirdine, etravirine, rilpivirine, doravirine)

Anti-Hepatitis C antiretroviral therapies
Ts:
•	Hepatitis C virus NS3/4A protease inhibitors [–previr] (class)
o	Asunaprevir (ingredient)
o	Boceprevir (ingredient)
o	Grazoprevir (ingredient)
o	Glecaprevir (ingredient)
o	Paritaprevir (ingredient)
o	Simeprevir (ingredient)
o	Telaprevir (ingredient)

Cs:
•	Pegylated interferon (ingredient)
•	Ribavirin (ingredient)


Drugs targeting the renin–angiotensin system
ACE inhibitors (class)
ARBs (class)
Possible comparator(s): Thiazides and thiazide-like diuretics (class) and calcium channel blockers (class)



